Research programme: cancer stem cell therapy - NeoStem Oncology

Drug Profile

Research programme: cancer stem cell therapy - NeoStem Oncology

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer NeoStem Oncology
  • Class Cancer vaccines; Dendritic cell vaccines; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Glioblastoma
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (SC, Injection)
  • 11 Sep 2014 NeoStem Oncology licenses patents covering methods for use of apoptotic cells to deliver antigen to dendritic cells from Rockefeller University
  • 08 May 2014 NeoStem acquires California Stem Cell and renames it NeoStem Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top